文献速递神经眼科小儿眼科与斜弱视

儿童视神经炎前瞻性结局研究:两年结果

The Pediatric Optic Neuritis Prospective Outcomes Study: Two-Year Results.
PubMed 文献 · Ophthalmology · 2022-03-29

儿童视神经炎前瞻性结局研究(PON1)在美国和加拿大23家儿童眼科或神经眼科门诊纳入44名3至16岁以下儿童,28名完成2年随访。尽管就诊时视力差,多数患儿6个月内视力明显改善并维持至2年;相关的神经系统自身免疫诊断常见。

要点

  • 28名完成2年随访的患儿中,79%在2年时视力达年龄正常水平,66%视力达20/20或更好。
  • 2年最终诊断包括孤立性视神经炎39%、MOG抗体相关脱髓鞘29%、多发性硬化14%、NMOSD 11%、急性播散性脑脊髓炎7%。
  • 5名(18%)患儿出现视神经炎再次发作(3例复发和2例新发),其中2名(7%)为后续复发性视神经炎,均患多发性硬化。

核心结论

  • 尽管就诊时视力差,多数患儿6个月内视力明显改善并维持至2年;相关的神经系统自身免疫诊断常见;5名(18%)患儿出现视神经炎再次发作(3例复发和2例新发)。

研究设计与样本

  • 非随机观察性研究,在美国和加拿大23家儿童眼科或神经眼科门诊进行。
  • 初始纳入44名3至16岁以下儿童,其中28名(64%)完成了2年研究访视。
  • 参与者在研究者酌情决定下接受治疗。

主要发现

  • 28名完成2年结局评估的参与者中位入组年龄10.3岁(范围5-15),46%为女性,68%就诊时为单侧视神经炎。
  • 2年最终诊断包括孤立性视神经炎11例(39%)、MOG抗体相关脱髓鞘8例(29%)、多发性硬化4例(14%)、NMOSD 3例(11%)、急性播散性脑脊髓炎2例(7%)。
  • 2名参与者(7%;95%CI 1-24)出现后续复发性视神经炎(另有1名未完成2年访视者),均患多发性硬化;另2名参与者(7%)在未受累眼出现新发作。
  • 平均就诊时高对比度视力(HCVA)为0.81 logMAR(约20/125),改善至6个月0.14 logMAR(约20/25-2)、1年0.12 logMAR(约20/25-2)、2年0.11 logMAR(20/25-1)(95%CI -0.08至0.3 [20/20+1-20/40-1])。
  • 24名参与者(79%)2年时视力达年龄正常水平(95%CI 60-90);21名参与者(66%)视力达20/20或更好。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Pediatric optic neuritis (ON) is a rare disease that has not been well characterized. The Pediatric ON Prospective Outcomes Study (PON1) was the first prospective study to our knowledge aiming to evaluate visual acuity (VA) outcomes, including VA, recurrence risk, and final diagnosis 2 years after enrollment. DESIGN: Nonrandomized observational study at 23 pediatric ophthalmology or neuro-ophthalmology clinics in the United States and Canada. PARTICIPANTS: A total of 28 (64%) of 44 children initially enrolled in PON1 (age 3-<16 years) who completed their 2-year study visit. METHODS: Participants were treated at the investigator's discretion. MAIN OUTCOMES MEASURES: Age-normal monocular high-contrast VA (HCVA). Secondary outcomes included low-contrast VA (LCVA), neuroimaging findings, and final diagnoses. RESULTS: A total of 28 participants completed the 2-year outcome with a median enrollment age of 10.3 years (range, 5-15); 46% were female, and 68% had unilateral ON at presentation. Final 2-year diagnoses included isolated ON (n = 11, 39%), myelin oligodendrocyte glycoprotein-associated demyelination (n = 8, 29%), multiple sclerosis (MS) (n = 4,14%), neuromyelitis optica spectrum disease (NMOSD) (n = 3, 11%), and acute disseminated encephalomyelitis (n = 2, 7%). Two participants (7%; 95% confidence interval [CI], 1-24) had subsequent recurrent ON (plus 1 participant who did not complete the 2-year visit); all had MS. Two other participants (7%) had a new episode in their unaffected eye. Mean presenting HCVA was 0.81 logarithm of the minimum angle of resolution (logMAR) (∼20/125), improving to 0.14 logMAR (∼20/25-2) at 6 months, 0.12 logMAR (∼20/25-2) at 1 year, and 0.11 logMAR (20/25-1) at 2 years (95% CI, -0.08 to 0.3 [20/20+1-20/40-1]). Twenty-four participants (79%) had age-normal VA at 2 years (95% CI, 60-90); 21 participants (66%) had 20/20 vision or better. The 6 participants without age-normal VA had 2-year diagnoses of NMOSD (n = 2 participants, 3 eyes), MS (n = 2 participants, 2 eyes), and isolated ON (n = 2 participants, 3 eyes). Mean presenting LCVA was 1.45 logMAR (∼20/500-2), improving to 0.78 logMAR (∼20/125+2) at 6 months, 0.69 logMAR (∼20/100+1) at 1 year, and 0.68 logMAR (∼20/100+2) at 2 years (95% CI, 0.48-0.88 [20/50+1-20/150-1]). CONCLUSIONS: Despite poor VA at presentation, most children had marked improvement in VA by 6 months that was maintained over 2 years. Associated neurologic autoimmune diagnoses were common. Additional episodes of ON occurred in 5 (18%) of the participants (3 relapses and 2 new episodes).

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Pineles SL, Henderson RJ, Repka MX, et al. The Pediatric Optic Neuritis Prospective Outcomes Study: Two-Year Results. Ophthalmology. 2022. PMID: 35364222. doi:10.1016/j.ophtha.2022.03.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。